Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

CSL's Privigen (human immunoglobulin) receives European approval for measles pre- and post-exposure prophylaxis
Protein therapy, infectious disease, immunoglobulin, measles, passive immunization, immunocompromised patients - Read more

Cencora, Gilead Sciences expand partnership to grow CAR-T therapy access across U.S. treatment centers
Distribution agreement, oncology, cell therapy, CAR-T, commercialization - Read more

Alnylam Pharmaceuticals, Inceptive Nucleics partner on AI-driven siRNA drug discovery, $30M upfront, up to $2B total
Research collaboration, AI/ML, drug discovery, siRNA, milestone payments - Read more

Mineralys Therapeutics pays Tanabe Pharma $200M upfront to eliminate lorundrostat royalties ahead of FDA decision
Licensing deal, small molecule, cardiovascular, milestone payments, royalties - Read more

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.

Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.

Learn more and book a free strategy call on our website.

Innovent Biologics' (arcotatug tavatecan) hits Ph3 win in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma
Antibody-drug conjugate, cancer, gastric cancer, CLDN18.2, exatecan payload - Read more

Ona Therapeutics raises $86.6M Series B to advance lead ADC into clinical studies
Oncology, antibody-drug conjugate, breast cancer, colorectal cancer, platform technology, clinical-stage - Read more

Parabilis plans up to $476M IPO, advancing peptide drug zolucatetide for desmoid tumors
Peptide therapeutics, oncology, rare disease, small molecule, clinical-stage - Read more

Haga Bioscience raises $2.3M Seed funding, advancing spatial RNA biomarker discovery and clinical translation
Spatial biology, biomarker discovery, RNA diagnostics, oncology, preclinical - Read more

Jade Biosciences prices $150M public offering to fund autoimmune disease clinical trials
Clinical-stage, autoimmune, biotechnology - Read more

Celcuity prices upsized $500M convertible notes offering, solid tumor targeted therapies
Clinical-stage, oncology, solid tumors, targeted therapy - Read more

Axsome Therapeutics settles all Sunosi patent litigation, blocking generic competition until 2040
Small molecule, narcolepsy, competitive, strategic - Read more

FDA accepts Absentia Labs' AI liver injury prediction model into ISTAND qualification program
Small molecule, hepatology, AI drug development, regulatory - Read more

FDA issues draft guidance to help developers leverage existing science for gene therapy submissions
Gene therapy, rare disease, regulatory, operational - Read more

FDA Acting Chief Diamantas meets rare disease groups to restore confidence after Makary's turbulent tenure
Rare disease, regulatory, operational, strategic - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Eli Lilly, Boehringer Ingelheim pull back €2B+ ($2.33B) Germany investments over healthcare spending cuts
GLP-1, metabolic disease, financial, operational, competitive - Read more

FDA issues untitled letter to QOL Medical over misleading Sucraid promotional emails with eye-catching graphics
Oral enzyme replacement therapy, rare disease, regulatory, operational - Read more

ADC Therapeutics' Zynlonta (loncastuximab tesirine) Ph3 trial reveals 27 deaths, raising safety concerns in diffuse large B cell lymphoma
Antibody-drug conjugate, cancer, diffuse large B cell lymphoma, anti-CD19, rituximab combination, lymphoma - Read more

FDA issues warning letter to Medline Industries over recurring bacterial contamination at multiple drug facilities
Manufacturing quality, drug safety, operational, financial - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here